Stoke Therapeutics, Inc. Stock News

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.66 per share a year ago.

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit

STOK went down steadily over the past two years. Its derisking Dravet data did not help either.

BEDFORD, Mass.--( BUSINESS WIRE )--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression w

On Nov 14, Stoke Therapeutics reported interim data from their p1/2 trials in Dravet Syndrome, a severe and progressive genetic epilepsy. Since the news, the stock has declined 41%, from $12.49 on Nov

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 4.35% and 2.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st

Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

After losing some value lately, a hammer chart pattern has been formed for Stoke Therapeutics, Inc. (STOK), indicating that the stock has found support. This, combined with an upward trend in earnings

Although the general rule of thumb is to avoid equities with heavy short interest, the new normal has brought with it new paradigms. One of these fresh approaches urges speculators to acquire short-sq

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 10% and 19.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit

Stoke Therapeutics (NASDAQ: STOK ) reported its Q4 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Stoke Therapeutics missed estimated earnings by 6.45%, reporting an EPS of … Full story available on Benzinga.com

Stoke Therapeutics press release (STOK): Q4 GAAP EPS of -$0.66 misses by $0.04.As of December 31, 2021, Company had $220.4 million in cash, cash equivalents, marketable securities,…